William W Stoops
Overview
Explore the profile of William W Stoops including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
2346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stoops W, Shellenberg T, Regnier S, Cox D, Adatorwovor R, Hays L, et al.
Drug Alcohol Depend
. 2025 Mar;
271:112642.
PMID: 40088641
Introduction: Limited prospective research has evaluated the health benefits associated with changing levels of drug use, aside from complete abstinence. This study determined whether lower levels of cocaine use impacted...
2.
Moore C, Stoops W
Pharmacol Biochem Behav
. 2024 Nov;
247():173928.
PMID: 39613192
No abstract available.
3.
Stoops W, Shellenberg T, Regnier S, Cox D, Adatorwovor R, Hays L, et al.
J Neuroimmunol
. 2024 Nov;
397:578470.
PMID: 39504756
This study determined the effects of reduced cocaine use on immune function. Treatment seeking participants with Cocaine Use Disorder enrolled in a 12-week contingency management trial to reduce cocaine use....
4.
Shellenberg T, Strickland J, Bergeria C, Regnier S, Stoops W, Lile J
Exp Clin Psychopharmacol
. 2024 May;
32(5):518-528.
PMID: 38695809
Disordered cannabis use is linked to social problems, which could be explained by a subjective devaluation of nondrug social contexts and/or an overvaluation of cannabis-paired options relative to nondrug alternatives....
5.
Bergeria C, Gipson C, Smith K, Stoops W, Strickland J
Neurosci Biobehav Rev
. 2024 Mar;
160:105618.
PMID: 38492446
Within addiction science, incubation of craving is an operational label used to describe time-dependent increases in drug seeking during periods of drug deprivation. The purpose of this systematic review was...
6.
Lile J, Shellenberg T, Babalonis S, Hatton K, Hays L, Rayapati A, et al.
Psychopharmacology (Berl)
. 2024 Feb;
241(6):1227-1236.
PMID: 38383903
Rationale: Understanding mechanisms of drug use decisions will inform the development of treatments for opioid use disorder (OUD). Decision-making experiments using neurobehavioral approaches require many trials or events of interest...
7.
Sadek S, Khatri S, Kipp Z, Dunn K, Beckmann J, Stoops W, et al.
Neuropharmacology
. 2023 Dec;
245:109816.
PMID: 38128606
The opioid use landscape has recently shifted to include xylazine, a veterinary anesthetic, as an adulterant in the fentanyl supply. The health impacts of xylazine as an emerging fentanyl adulterant...
8.
Stoops W
Exp Clin Psychopharmacol
. 2023 Dec;
31(6):989-990.
PMID: 38127504
This editorial focuses on William W. Stoops time as editor of Stoops ends his time with gratitude for all who have contributed to the journal's success over the past years,...
9.
Regnier S, Shellenberg T, Koffarnus M, Cox D, Lile J, Rush C, et al.
Drug Alcohol Depend
. 2023 Nov;
253:111030.
PMID: 38006674
Background: Contingency Management (CM) is being piloted as a treatment for stimulant use disorder in several US states, highlighting the need for treatment optimization. One important goal of optimization is...
10.
Khatri S, Ulangkaya H, Maher E, Sadek S, Hong M, Woodcox A, et al.
Neuropharmacology
. 2023 Oct;
242:109773.
PMID: 37865136
Individuals with opioid use disorder (OUD) frequently use other substances, including cocaine. Opioid withdrawal is associated with increased likelihood of cocaine use, which may represent an attempt to ameliorate opioid...